- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
BioElectronics Corporation will present new research findings during the World Congress of International Neuromodulation Society.
BioElectronics Corporation (OTCPINK:BIEL) will showcase new research findings during the World Congress of International Neuromodulation Society.
As quoted in the press release:
We are pleased to announce that the scientific committee of the International Neuromodulation Society accepted our research “Increasing Cardiac Output in Subjects with Orthostatic Hypotension: Neuromodulation Using Pulsed Shortwave Therapy” for both ORAL and POSTER presentation.
This research is the culmination of 3 years of research in the Clinical Science & Engineering Research Laboratory, located at Binghamton University, New York. Sree Koneru, Ph.D., Director of Electroceutical Research, said, “The scientific community did not have a good understanding of the mechanism behind pulsed shortwave therapy. Our research work indicates that ActiPatch works by regulating the activity of nerves, a process known as neuromodulation. Our data provides real-time evidence of physiological activity.” Dr. Koneru, along with his mentor, Professor Kenneth McLeod, Ph.D., observed that regulating the activity of nerves in the feet using pulsed shortwave therapy technology can increase cardiac output (the amount of blood pumped by the heart per minute).
The research finding is exciting news for the company because they indicate that ActiPatch technology can be developed to treat other chronic conditions such as migraines, overactive bladder and chronic wounds. The 13th World Congress of the International Neuromodulation Society is scheduled to meet in Edinburgh, Scotland from May 27-31, 2017.
About BioElectronics Corporation
BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; Allay® Menstrual Pain Therapy. For more information, please visit www.bielcorp.com.
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.